Director/PDMR Shareholding

Jun 9, 2014

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsDirector ShareholdingDirector/PDMR Shareholding
RNS Number : 1902J
Advanced Medical Solutions Grp PLC
09 June 2014
 



9 June 2014

Advanced Medical Solutions Group plc (“AMS” or the “Company”)

Directors’ shareholdings

Advanced Medical Solutions Group plc (AIM:AMS), the global medical technology company, announces that the Board, following a recommendation from the Remuneration Committee, has granted new share options to the following Directors under the Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’) on 6 June 2014.   The vesting period of these options is subject to certain performance criteria over a 3 year period.

Director

Options prior to grant

Options granted

Resultant holding

Chris Meredith, Chief Executive Officer

794,515

210,753

1,005,268

Mary Tavener, Group Finance Director

537,091

148,817

685,908

 

For further information:

Advanced Medical Solutions Group plc

Mary Tavener, Group Finance Director +44 (0) 1606 545 508

Investec (NOMAD)

Daniel Adams +44 (0) 20 7597 5970

END


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RDSBSGDLCUGBGSC

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.